Shortly after the recognition by Dicke that wheat proteins, in particular gluten, are the specific precipitant of a relapse in children with coeliac disease, it was suggested that this disorder was because of a failure of the small intestinal mucosa of coeliac patients to detoxify gluten. Frazer showed by careful feeding studies that, whereas a peptic tryptic-pancreatic digest of gluten induced a relapse in these patients, after incubation with normal intestine, the resultant mixture was no longer toxic. Since that period the missing peptidase hypothesis has waxed and waned in popularity, waging a love-hate relationship with the so-called immunological hypothesis.
Various ingenious methods have been applied to test the missing peptidase hypothesis. Early whole body studies were performed by administering large quantities of gluten to normal volunteers and to patients with coeliac disease with subsequent measurements of amino acids, in particular glutamine concentrations in the serum, in the hope that they would reflect altered handling of the peptides by the brush border. 1-3 Serum glutamate concentrations were found to be significantly higher in the coeliac patients and it was concluded that gluten digestion was not specifically impaired. It was, however, clear that this approach lacked sensitivity because of the various factors affecting postprandial amino acid concentrations in the peripheral blood and biochemical techniques were therefore applied directly to the jejunal mucosa.
Examination of mucosal digests of gluten peptic-tryptic fractions showed a distinct peptide finger print when coeliac mucosa was compared with control intestine. Staining studies suggested that this peptide was rich in proline. 4 30 Transglutaminase activity has long been recognised in other tissue sites. Plasma fibrin stabilising activity (factor XIII) has been shown to be due to transglutaminase activity31 and the enzyme has been implicated in cell-cell interaction,32 keratin formation,33 34 endocytosis35 36 and cell proliferation and neoplasia,37 as well as in fibrin3' and seminal plug38 stabilisation. It has also been implicated in lymphocytes,39 macrophages40 and erythrocytes41 42 and in drug43 reactions. Gliadin would be expected to be an excellent substrate for this enzyme and indeed has been found to be so. 44 An early observation, little studied at present, is that gluten which has been selectively deamidated -that is, in which the amides of the glutamine residues are cleaved without effecting the polypeptide backbone, is no longer toxic to patients with coeliac disease.45 This observation strongly implicates defects in the metabolism, or binding of the glutamine residues in the pathogenesis of coeliac disease. Transglutaminase is an enzyme with such a role and deamidation of gluten renders it no longer a substrate for this enzyme. 44 Transglutaminase activity has been shown in normal jejunal biopsy specimens in man,46 which may explain the toxicity of gluten to normal volunteers when given in sufficient quantities.47 Moreover, the enzyme activity is increased in biopsies from patients with coeliac disease in remission and in relapse44 and thus it might have an important role in gluten cell membrane interactions, a key step in most hypotheses of coeliac disease. These studies also raise the question of whether we have been searching for an enzyme defect, when increased activity may more adequately explain the pathological picture. Further studies, including the cellular and subcellular localisation of the activity, are necessary in normal and in coeliac mucosa. These observations do, however, indicate new biochemical approaches to the study of coeliac disease Recent interest in glutamate and glutamine metabolism by rat small intestine have stressed the importance of intracellular (cytosolic and mitochondrial) glutaminase, glutamate dehydrogenase and aspartate and alanine amino-transferases in enterocyte intermediate metabolism. 48 49 50 There is a clear need for similar studies in man of normal and gluten-sensitive subjects.
There is therefore a need for a new detailed examination of gluten degradation. transfer, binding and metabolism by intestinal mucosa from control subjects and particularly from patients with coeliac disease in full remission. In vitro techniques with organ culture procedures should be coupled with in vivo perfusion, or metabolic balance studies. This approach should have preceded the large number of in vitro gliadin cytotoxicity studies, which so far have yielded only conflicting and confusing results. It is surely to the benefit of immunological and biochemical protagonists, that the basic biochemistry of gliadin handling by the small gut be elucidated in detail. 
